DelveInsight’s, “H3N2 Infection Pipeline Insights 2026” Report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 Infection pipeline landscape. It covers the H3N2 Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the H3N2 Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the H3N2 Infection Pipeline @ H3N2 Infection Pipeline Outlook

Key Takeaways from the H3N2 Infection Pipeline Report

• In March 2026- Seqirus initiated a phase 3/3b Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.
• DelveInsight’s H3N2 Infection pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for H3N2 Infection treatment.
• The leading H3N2 Infection Companies such as Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara therapeutics, GRDG SCIENECES, FluGen Inc., Barinthus Biotherapeutics and others.
• Promising H3N2 Infection Pipeline Therapies such as FLU-IGIV, MVA-NP+M1, Saline, Grippol Quadrivalent, QIV or TIV and others.

Stay ahead with the most recent pipeline outlook for H3N2 Infection @ H3N2 Infection Treatment Drugs

The H3N2 Infection Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The H3N2 Infection Pipeline Report also highlights the unmet needs with respect to the H3N2 Infection.

H3N2 Infection Overview

Influenza A virus subtype H3N2 (A/H3N2) is a subtype of viruses that causes influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 viruses have circulated in humans since their pandemic emergence in 1968 and are generally associated with uncomplicated disease in young healthy adults. However, epidemics caused by H3N2 viruses have been more severe than those caused by seasonal H1N1 or influenza B viruses. Influenza viruses that normally circulate in pigs are called “variant” viruses when they are found in people. Influenza a H3N2 variant viruses (also known as “H3N2v” viruses) with the matrix (M) gene from the 2009 H1N1 pandemic virus were first detected in people in July 2011. H3N2 virus infections boost non-neutralizing H3N2 antibodies in middle-aged individuals, potentially leaving many of them in a perpetual state of 3c2. Because the influenza virus changes so frequently it is hard to identify and treat and even harder to develop a vaccine months in advance of flu season. Symptoms are similar no matter what strain of influenza is circulating each year. Treatment may include antiviral medications if diagnosed early; otherwise, rest, lots of fluids, and OTC medications can help relieve symptoms.

H3N2 Infection Emerging Drugs Profile

• mRNA-1083: Moderna Therapeutics

mRNA-1083 is under development for the prevention of influenza virus infection caused by influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria strains and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in 18 to 79 years of age group. It is a combination vaccine of mRNA-1283, which encodes Receptor Binding Doman (RBD) and N-Terminal Domain (NTD) of the spike protein and mRNA-1010, which encodes hemagglutinin (HA) glycoproteins of influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria-lineages. It is administered through intramuscular route in the form of sterile liquid for injection. Currently, the drug is in Phase III stage of its clinical trial for the treatment H3N2 infection.

• CD-388: Cidara therapeutics

CD-388 is under development of the treatment and prevention of influenza virus A, seasonal influenza, pandemic influenza and influenza virus B infections. The drug candidate is a second generation, anti-viral Fc conjugate (AVC). It comprises of two moieties attached through a chemical linker. One is a targeting moiety (TM) that recognizes cell surface target and another is an effector moiety (EM) that is recognized by the immune system. It is administered through intramuscular and subcutaneous route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of H3N2 infection.

• PF-07845104: Pfizer

PF-07845104 is a prophylactic saRNA Vaccine developed by Pfizer. Its therapeutics area include infectious respiratory diseases. Currently, the drug is in phase I stage of its clinical trial for the treatment of H3N2 infection.

The H3N2 Infection Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of H3N2 Infection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for H3N2 Infection Treatment.
• H3N2 Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• H3N2 Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the H3N2 Infection market

Explore groundbreaking therapies and clinical trials in the H3N2 Infection Pipeline @ New H3N2 Infection Drugs

H3N2 Infection Companies

Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara therapeutics, GRDG SCIENECES, FluGen Inc., Barinthus Biotherapeutics and others.

H3N2 Infection Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

H3N2 Infection Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Learn about new drugs, pipeline developments with DelveInsight’s expert analysis @ H3N2 Infection Market Drivers and Barriers

Scope of the H3N2 Infection Pipeline Report

• Coverage- Global
• H3N2 Infection Companies- Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara therapeutics, GRDG SCIENECES, FluGen Inc., Barinthus Biotherapeutics and others.
• H3N2 Infection Pipeline Therapies- FLU-IGIV, MVA-NP+M1, Saline, Grippol Quadrivalent, QIV or TIV and others.
• H3N2 Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• H3N2 Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on H3N2 Infection Therapies and clinical trials @ H3N2 Infection Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. H3N2 Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. H3N2 Infection– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. mRNA-1083: Moderna Therapeutics
9. Drug name : Company name
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. CD-388: Cidara therapeutics
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. PF-07845104: Pfizer
16. Drug name : Company name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name : Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. H3N2 Infection Key Companies
23. H3N2 Infection Key Products
24. H3N2 Infection- Unmet Needs
25. H3N2 Infection- Market Drivers and Barriers
26. H3N2 Infection- Future Perspectives and Conclusion
27. H3N2 Infection Analyst Views
28. H3N2 Infection Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/h3n2-infection-pipeline-insight